✨ Medicines Classification
12 FEBRUARY 2009
NEW ZEALAND GAZETTE, No. 16
Schedule
Oxiconazole; except when specified elsewhere in this Schedule
Palifermin
Paliperidone
Panitumumab
Paracetamol; except when specified elsewhere in this Schedule
Paricalcitol
Pegvisomant
Pheniramine; except when specified elsewhere in this Schedule
Phenyltoloxamine
Picric acid
Polysulfated glycosaminoglycans; for injection except in intraocular viscoelastic products
Promethazine; except when specified elsewhere in this Schedule
Pyridoxal; in medicines containing more than 200 milligrams per recommended daily dose
Pyridoxamine; in medicines containing more than 200 milligrams per recommended daily dose
Pyrvinium
Raltegravir
Ranibizumab
Ranitidine; except when specified elsewhere in this Schedule; except in medicines containing 150 milligrams or less per dose unit which have received the consent of the Minister or the Director-General to their distribution as general sale medicines and which are sold in the manufacturer’s original pack containing not more than 7 days’ supply
Rasagilin
Rifampicin
Riluzole
Rimexolone
Rimonabant
Ruboxistaurin
Sabadilla
Schoenocoulon officinale
Scopolia carniolica
Selenium; except when specified elsewhere in this Schedule; except for oral use in medicines containing 150 micrograms or less per recommended daily dose; except for external use in medicines containing 3.5% or less of selenium sulphide
Sitagliptin
Sitaxentan
Sorafenib
Sumatriptan; except when specified elsewhere in this Schedule
Sugammadex
Sunitinib
Telbivudine
Thenyldiamine
Tipepidine
Tiprinavir
Tolpropamine
Tocilizumab
Trimeprazine; except when specified elsewhere in this Schedule
Trinitrophenol
Triprolidine; except when specified elsewhere in this Schedule
Varenicline
Vildagliptin
Vitamin A; for internal use in medicines containing more than 3,000 micrograms of retinol equivalents per recommended daily dose except in parenteral nutrition replacement preparations; for external use in medicines containing more than 1%
Vitamin D; for internal use in medicines containing more than 25 micrograms per recommended daily dose except in parenteral nutrition replacement preparations
Zinc; for internal use in medicines containing more than 25 milligrams per recommended daily dose; except for internal use in medicines containing 50 milligrams or less and more than 25 milligrams per recommended daily dose in packs which have received the consent of the Minister or the Director-General to their distribution as general sale medicines and which are sold in the manufacturer’s original pack and when labelled with a statement that the product may be dangerous if taken in large amounts or for long periods; except in parenteral nutrition replacement preparations
Zonisamide
Schedule 2
Restricted Medicines
Aspirin; in slow release forms; in enteric coated forms containing more than 300 milligrams per dose form; except when specified elsewhere in this Schedule
Azatadine; for oral use in adults and children over 2 years of age
Azelastine; in medicines for ophthalmic use containing 0.05% or less
Brompheniramine; for oral use medicines for adults and children over 2 years of age except when specified elsewhere in this Schedule
Butoconazole; for vaginal use
Chlorpheniramine; for oral use in medicines for adults and children over 2 years of age except when specified elsewhere in this Schedule
Dexchlorpheniramine; for oral use in medicines for adults and children over 2 years of age except when specified elsewhere in this Schedule
Dimenhydrinate; for oral use in medicines for adults and children over 2 years of age except when specified elsewhere in this Schedule
Diphenhydramine; for oral use in medicines for adults and children over 2 years of age except when specified elsewhere in this Schedule
Diphenylpyraline; for oral use in medicines for adults and children over 2 years of age except when specified elsewhere in this Schedule
Doxylamine; for oral use in medicines for adults and children over 2 years of age except when specified elsewhere in this Schedule
Hydrocortisone and hydrocortisone acetate but no other esters of hydrocortisone; for dermal use in medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base with no other ingredient except an antifungal and in a quantity of 30 grams or less or 30 millilitres or less per container; in rectal medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base and in combination with a local anaesthetic and in a quantity of 35 grams or less per container or up to 12 suppositories per pack.
Ibuprofen; for oral use in tablets or capsules containing up to 400 milligrams per dose form and in packs containing not more than 50 dose units and which have received the consent of the Minister or the Director-General to their
Next Page →
✨ LLM interpretation of page content
🏥
Classification of Medicines
(continued from previous page)
🏥 Health & Social WelfareMedicines, Classification, Prescription, Restricted, Pharmacy-only
NZ Gazette 2009, No 16